Antibodies for treatment and diagnosis of inflammatory bowel disease

Patent metadata

Field	Value
Publication number	US-10647760-B2
Application number	US-201616060766-A
Country	US
Kind code	B2
Filing date	Dec 9, 2016
Priority date	Dec 11, 2015
Publication date	May 12, 2020
Grant date	May 12, 2020

Abstract

The invention relates to the diagnosis and treatment of diseases, including inflammatory disorders, proliferative disorders and autoimmune diseases. The invention provides, and involves the use of, antibody molecules that bind: i) lysozyme, ii) neutrophil elastase, iii) tissue inhibitor of metalloproteinase-1 (TIMP-1), or iv) the D domain of Tenascin-C. The invention also relates to the use of antibody molecules that bind v) the IIICS isoform of fibronectin, vi) the Extra Domain-B (ED-B) of fibronectin, vii) matrix-metalloproteinase 3 (MMP3), or viii) the A1 domain of tenascin-C in the diagnosis and treatment of inflammatory disorders such as inflammatory bowel disease.

First claim

The invention claimed is:

1. An antibody molecule that binds domain D of Tenascin-C, wherein the antibody molecule comprises a VH domain comprising a framework and a set of complementarity determining regions HCDR1, HCDR2 and HCDR3, and a VL domain comprising a framework and a set of complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein:
HCDR1 has the amino acid sequence of SEQ ID NO: 27;
HCDR2 has the amino acid sequence of SEQ ID NO: 91;
HCDR3 has the amino acid sequence of SEQ ID NO: 29;
LCDR1 has the amino acid sequence of SEQ ID NO: 30;
LCDR2 has the amino acid sequence of SEQ ID NO: 31; and
LCDR3 has the amino acid sequence of SEQ ID NO: 92.

2. The antibody molecule according to claim 1 , wherein the VH domain comprises or consist of the amino acid sequence of SEQ ID NO: 89, and/or the VL domain comprises or consist of the amino acid sequence of SEQ ID NO: 90.

3. The antibody molecule according to claim 1 wherein the antibody molecule is or comprises a single chain Fv (scFv), is a small immunoprotein (SIP), is a diabody, or is an IgG molecule.

4. A conjugate comprising an antibody molecule according to claim 1 and an immunosuppressive or anti-inflammatory agent.

5. The conjugate according to claim 4 , wherein the anti-inflammatory agent is a cytokine.

6. The conjugate according to claim 4 wherein the conjugate is a fusion protein comprising the antibody molecule and an immunosuppressive agent, an anti-inflammatory agent, or a cytokine.

7. A conjugate comprising an antibody molecule according to claim 1 and a detectable label.

Assignees

• Philogen Spa

Inventors

• Wulhfard Sarah
• Villa Alessandra
• Pemberton Ross Catherine
• Pretto Francesca
• Fleetwood Filippa

Classifications

• A61K47/6813

  the drug being a peptidic cytokine, e.g. an interleukin or interferon · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/60

  characterized by non-natural combinations of immunoglobulin fragments · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title